CP4ACS - Delphi Study to Determine Appropriateness of STEMI Quality Indicators in Belgium

March 22, 2022 updated by: Dr. Kris Vanhaecht, European Pathway Association

Quality of Care for STEMI - Patients. a Research to Determine Appropriateness of STEMI Quality Indicators in Belgium, a RAND/UCLA Modified Delphi Study

RAND/UCLA modified Delphi study on quality indicators for STEMI to determine the appropriateness of quality indicators retrieved from literature and guideline review. We aim to engage 20 cardiologists and 20 nurses with relevant experience in the care for STEMI patients.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

32

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Belgium
        • KU Leuven

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

We aim to engage 20 cardiologists and 20 cardio nurses, all experienced in the care for STEMI patients

Description

Inclusion Criteria:

  • cardiologist or cardio nurse with relevant experience in the care for STEMI patients

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
cardiologists
study coordinators
registred nurses

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
validated quality indicators for STEMI care in belgium (both on patient and on hospital level)
Time Frame: 2 months
33 experts in cardioloy, cardio nursing and quality rated quality indicators for STEMI care in belgian hospitals on a 9 point Likert Scale. All indicators with a median score between 7 and 9 were discussed in an expert panel. The expert panel selected validated quality inidicators for STEMI care.
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

European Pathway Association

Collaborators

Universitaire Ziekenhuizen KU Leuven
KU Leuven

Investigators

  • Principal Investigator: Kris Vanhaecht, dr, KU Leuven

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2013

Primary Completion (Actual)

November 1, 2013

Study Completion (Actual)

November 1, 2013

Study Registration Dates

First Submitted

January 5, 2014

First Submitted That Met QC Criteria

January 7, 2014

First Posted (Estimate)

January 8, 2014

Study Record Updates

Last Update Posted (Actual)

April 4, 2022

Last Update Submitted That Met QC Criteria

March 22, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CP4ACS\2013\1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on STEMI

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe